Beractant is a natural bovine lung surfactant used to treat Respiratory Distress Syndrome (RDS) in neonates. It reduces surface tension in the lungs and replaces the missing surfactant. Beractant is administered intratracheally in doses of 100 mg phospholipids/kg birth weight for prophylaxis or rescue treatment of RDS. It has an immediate onset when given intratracheally and an unknown half-life. Common adverse effects include apnea, bradycardia, pulmonary hemorrhage, and infection. Nurses must monitor patients closely during and after administration for safety and efficacy.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Beractant is a natural bovine lung surfactant used to treat Respiratory Distress Syndrome (RDS) in neonates. It reduces surface tension in the lungs and replaces the missing surfactant. Beractant is administered intratracheally in doses of 100 mg phospholipids/kg birth weight for prophylaxis or rescue treatment of RDS. It has an immediate onset when given intratracheally and an unknown half-life. Common adverse effects include apnea, bradycardia, pulmonary hemorrhage, and infection. Nurses must monitor patients closely during and after administration for safety and efficacy.
Beractant is a natural bovine lung surfactant used to treat Respiratory Distress Syndrome (RDS) in neonates. It reduces surface tension in the lungs and replaces the missing surfactant. Beractant is administered intratracheally in doses of 100 mg phospholipids/kg birth weight for prophylaxis or rescue treatment of RDS. It has an immediate onset when given intratracheally and an unknown half-life. Common adverse effects include apnea, bradycardia, pulmonary hemorrhage, and infection. Nurses must monitor patients closely during and after administration for safety and efficacy.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Beractant is a natural bovine lung surfactant used to treat Respiratory Distress Syndrome (RDS) in neonates. It reduces surface tension in the lungs and replaces the missing surfactant. Beractant is administered intratracheally in doses of 100 mg phospholipids/kg birth weight for prophylaxis or rescue treatment of RDS. It has an immediate onset when given intratracheally and an unknown half-life. Common adverse effects include apnea, bradycardia, pulmonary hemorrhage, and infection. Nurses must monitor patients closely during and after administration for safety and efficacy.
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOC, PDF, TXT or read online from Scribd
Download as doc, pdf, or txt
You are on page 1/ 4
BERACTANT Suspension—25 mg/ml suspended in
Drug class: natural lung surfactant 0.9% sodium chloride injection
Therapeutic actions: A natural bovine compound
containing lipids
and apoproteins that reduce surface tension and allow
expansion of the alveoli; replaces the surfactant Dosages:
missing Pediatric patients in the lungs of neonates suffering from RDS. Accurate determination of birth weight is essential for Indications: correct dosage. Beractant is instilled into the trachea Prophylactic treatment of infants at risk of developing using a catheter inserted into the endotracheal tube.
RDS; infants with birth weights less than 1250 g Prophylactic treatment: Give first dose of 100 mg or infants with birth weights more than 1250 g phospholipids/kg birth weight ( 4 ml/kg) soon have evidence of pulmonary immaturity after Rescue treatment of infants who have birth. Four doses can be administered in the first developed RDS 48 hours of life. Give no more than every 6 hr. Contraindications:
Because beractant is used an emergency drug
in Rescue treatment: Administer 100 mg phospholipids acute respiratory situations, the benefits usually outweigh /kg birth weight (4 ml/kg) intratracheally. Administer any possible risks. the first dose as soon as possible after the Available forms: diagnosis of RDS is made and patient is on the ventilator. pulmonary hemorrhage, apnea,
Repeat doses can be given based on clinical pneumodiastinum, emphysema
improvement 5. Other: Sepsis, non pulmonary infection And blood gases. Administer subsequent doses no sooner than every 6 hr. Nursing considerations:
Route Onset Peak oximeter, Intratracheal Immediate Hours endotracheal tube position and patency, chest movement; Metabolism: Normal surfactant metabolic pathways; T ½: Unknown ECG, P.BP, peripheral perfusion and arterial pressure(desirable); Distribution: Lung tissue Oxygen saturation, blood gases, CBC;
muscular activity, facial expressions, reflexes
Adverse Effects 1. CNS: seizures
2. CV: patent ductus arteriosus, intraventricular
hemorrhage,
Hypotension, bradycardia Monitor ECG and transcutaneous oxygen 3. Hematologic: hyperbilirubinemia, saturation thrombocytopenia continually during administration. 4. Respiratory: pneumothorax, pulmonary air leak, Ensure that endotracheal tube is in the correct unused vials warmed to room temperature may position, be returned to refrigerator within 8 hours of warming. with bilateral chest movement and lung sounds. Insert 5 french catheter into the endotracheal Have staff view manufacturer’s teaching video tube; do not instill into the mainsteam bronchus. before Instill dose quickly; inject one-fourth dose over regular use to cover all technical aspects of 2-3 seconds; remove catheter and reattach administration. infant to ventilator at least Suction the infant immediately before 30 seconds or until stable; repeat procedure administration, but administering Do not suction for 1 hour after administration One-fourth dose at a time. unless Do not suction infant for 1 hour after Clinically necessary. completion of full dose; do not flush catheter. Inspect via for discoloration . Vial should contain off-white Continually monitor patient’s color, lung To brown liquid. Gently mix. Warm to room sounds, ECG, oximeter, and blood gas temperature readings during administration and for at least 30 min. afeter. Before using – 20 min standing or 8 min warned by hand. Teaching points:
Don’t use other warning methods. Details of drug effects and
administration are best Store drug in refrigerator. Protect the light. incorporated into parent’s Enter drug vial comprehensive teaching only once. Discard remaining drug after use. program. Unopened ,
